Illumina: New Leadership and a New Strategy. Our Conviction Has Changed. - 7investing 7investing
Stock Tips Mobile Menu Dropdown Icon

Illumina: New Leadership and a New Strategy. Our Conviction Has Changed.

Illumina has replaced its CEO, its Chairman, and its strategic priorities. What will this mean for investors?

September 14, 2023

Genomic sequencing leader Illumina (Nasdaq: ILMN) has been in the news a lot lately. And for all the wrong reasons.

Our 7investing team was initially drawn to Illumina’s undisputed leadership position, accounting for for more than 90% of the world’s high-throughput sequencing volume and benefiting from scientific breakthroughs like CRISPR and government-funded precision medicine initiatives.

Yet the company has been under the gun this year. In April, the Federal Trade Commission demanded that Illumina divest its newly-re-acquired GRAIL subsidiary, believing it led to uncompetitive business practices. On top of that, activist investor Carl Icahn launched a proxy battle that ultimately resulted in replacing both the Chairman and the CEO.

What will all of this mean for investors? Now priced at a 52-week low, is Illumina’s stock still a buy?

7investing advisor Simon Erickson shares a deep-dive into Illumina’s history, an analysis of its current situation, and whether 7investing thinks the stock is a buy, hold, or sell in his complete Company Update.

Reminder: You must be logged in with an active 7investing membership to view this Company Updates. To get started with 7investing in 30 seconds and for just $1, please click here.

a button saying "Read Full company update"

Join 7investing's Free Email List

Already a 7investing member? Log in here.